Datasheet is currently unavailable. Try again or CONTACT US
ATG13 phospho S318 Antibody
Rabbit Polyclonal
40 References
600-401-C49S
600-401-C49
25 µL
100 µg
Liquid (sterile filtered)
Liquid (sterile filtered)
WB, ELISA, IF, FC, Dot Blot, Multiplex
Human
Rabbit
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-ATG13 pS318 (RABBIT) Antibody - 600-401-C49
rabbit anti-ATG13 pS318 Antibody, ATG-13, ATG 13, Autophagy-related protein 13, KIAA0652
Rabbit
Polyclonal
IgG
Target Details
ATG13 - View All ATG13 Products
Human
Phosphorylation
Conjugated Peptide
Anti-ATG13 pS318 antibody was prepared by repeated immunizations with a synthetic peptide corresponding to the region near S318 of ATG13.
This affinity-purified antibody is directed against the phosphorylated form of human ATG13 protein at the pS318 residue. The product was affinity purified from monospecific antiserum by immunoaffinity purification. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against human ATG13 pS318 protein and the antibody is specific for the phosphorylated form of the protein. Reactivity with non-phosphorylated human ATG13 is minimal by ELISA and western blot. A BLAST analysis was used to suggest cross reactivity with ATG13 from human based on 100% sequence homology with the immunogen. Reactivity against homologues from other sources is not known.
Application Details
Dot Blot, ELISA, WB
FC, IF, Multiplex
- View References
This affinity purified antibody has been tested for use in ELISA and by western blot. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 56.6 kDa in size corresponding to human phosphorylated ATG13 protein by western blotting in the appropriate stimulated tissue or cell lysate or extract.
Formulation
1.2 by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
ATG13 is a target of the TOR kinase signaling pathway that regulates autophagy through the control of the phosphorylation status of ATG13 and ULK1 through their stable complex, and the regulation of ATG13-ULK1-RB1CC1. ATG13 also forms a stable complex with FIP200. Ulk1 phosphorylates ATG13 on S318 and promotes its release to damaged mitochondria. Autophagy is a normal process in eukaryotes required for turnover of cellular components during starvation and stress. It plays an essential role in cellular differentiation, cell death and aging. Defects in this evolutionarily conserved process may contribute to certain human diseases such as cancer, neurodegenerative diseases, muscular disorders and pathogen infections. ATG13 is one of several ATG genes required for autophagosome formation in mammalian cells. mTOR interacts with this complex in a nutrient dependent manner and phosphorylates Atg13 and ULK1.
Ikeda R et a. (2023). Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox-independent stress response. EMBO J.
Applications
WB, IB, PCA
Brobbey C et al. (2023). Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer. Sci Rep.
Applications
WB, IB, PCA
Kallergi E et al. (2023). Profiling of purified autophagic vesicle degradome in the maturing and aging brain. Neuron.
Applications
WB, IB, PCA
Martínez-Martínez, E et al. (2022). A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts. International Journal of Molecular Sciences
Applications
WB, IB, PCA
Kallergi E et al. (2022). Dendritic autophagy degrades postsynaptic proteins and is required for long-term synaptic depression in mice. Nat Commun.
Applications
WB, IB, PCA
Zhang Y et al. (2022). M6 A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1. Cancer Sci.
Applications
WB, IB, PCA
Tsang T et al. (2022). BRAFV600E-Driven Lung Adenocarcinoma Requires Copper to Sustain Autophagic Signaling and Processing. Mol Cancer Res.
Applications
WB, IB, PCA
Ktena N et al. (2022). Autophagic degradation of CNS myelin maintains axon integrity. Cell Stress.
Applications
WB, IB, PCA
Ryu HY et al. (2021). GSK3B induces autophagy by phosphorylating ULK1. Exp Mol Med.
Applications
WB, IB, PCA
Munson, MJ et al. (2021). GAK and PRKCD are positive regulators of PRKN-independent mitophagy. Nature Communications
Applications
WB, IB, PCA
Humbert M et al. (2021). Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death Differ.
Applications
WB, IB, PCA
Carinci M et al. (2021). TFG binds LC3C to regulate ULK1 localization and autophagosome formation. EMBO J.
Applications
WB, IB, PCA
Mercer TJ et al. (2021). Phosphoproteomic identification of ULK substrates reveals VPS15‐dependent ULK/VPS34 interplay in the regulation of autophagy. EMBO J.
Applications
WB, IB, PCA
Tsang T et al. (2020). Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol.
Applications
WB, IB, PCA
Ren, H et al. (2020). Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry
Applications
WB, IB, PCA
Thayer, JA et al. (2020). The PARK10 gene USP24 is a negative regulator of autophagy and ULK1 protein stability. Autophagy
Applications
WB, IB, PCA
Izumi et al. (2019). Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region. Scientific Reports
Applications
WB, IB, PCA
Jia R et al. (2019). Negative regulation of autophagy by UBA6-BIRC6-mediated ubiquitination of LC3. ELife
Applications
WB, IB, PCA
Wirth M et al. (2019). Autophagy Pathway Mapping to Elucidate the Function of Novel Autophagy Regulators Identified by High-Throughput Screening. Methods Mol Biol.
Applications
WB, IB, PCA
Luhr M et al. (2019). The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress. J Biol Chem.
Applications
WB, IB, PCA
Wang B et al. (2019). ULK1 and ULK2 regulate stress granule disassembly through phosphorylation and activation of VCP/p97. Mol Cell.
Applications
WB, IB, PCA
Fuqua, JD et al. (2019). ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscle. Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology
Applications
WB, IB, PCA
Hagey et al. (2018). SOX2 regulates common and specific stem cell features in the CNS and endoderm derived organs. PLOS Genetics
Applications
IF, Confocal Microscopy; Multiplex Assay
Wang et al. (2018). Phosphorylation of ULK1 affects autophagosome fusion and links chaperone-mediated autophagy to macroautophagy. Nature Communications
Applications
WB, IB, PCA
Wallot-Hieke N et al. (2018). Systematic analysis of ATG13 domain requirements for autophagy induction. Autophagy.
Applications
WB, IB, PCA
Colecchia D et al. (2018). MAPK15 is part of the ULK complex and controls its activity to regulate early phases of the autophagic process. J Biol Chem.
Applications
WB, IB, PCA
Jeong, YT et al. (2018). The ULK1-FBXW5-SEC23B nexus controls autophagy. ELife
Applications
WB, IB, PCA
Jung J et al. (2017). Multiplex image-based autophagy RNAi screening identifies SMCR8 as ULK1 kinase activity and gene expression regulator. Elife
Applications
WB, IB, PCA
Xie Y et al. (2017). Assessment of posttranslational modifications of ATG proteins. Methods Enzymol.
Applications
E, EIA; FC, FACS, FLOW; WB, IB, PCA
Stork B et al (2017). Study of ULK1 Catalytic Activity and Its Regulation. Methods Enzymol.
Applications
WB, IB, PCA
Baron, O et al. (2017). Stall in Canonical Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in Neurodegeneration. Current Biology : Cb
Applications
WB, IB, PCA
Puente et al. (2016). Nutrient-regulated Phosphorylation of ATG13 Inhibits Starvation-induced Autophagy. Journal of Biological Chemistry
Applications
WB, IB, PCA
Park et al. (2016). The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14. Autophagy
Applications
WB, IB, PCA
Rosenberg et al. (2015). Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors. Journal of Biomolecular Screening
Applications
E, EIA
Jiao et al. (2015). Chaperone-like protein p32 regulates ULK1 stability and autophagy. Cell Death & Differentiation
Applications
WB, IB, PCA
Egan et al. (2015). Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Molecular Cell
Applications
WB, IB, PCA
Hieke et al. (2015). Expression of a ULK1/2 binding-deficient ATG13 variant can partially restore autophagic activity in ATG13-deficient cells. Autophagy
Applications
WB, IB, PCA
Puustinen P et al. (2014). CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol.
Applications
WB, IB, PCA
Nazio F, Strappazzon F, Antonioli M, et al. (2013). mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol.
Applications
WB, IB, PCA
Stanton MJ, Dutta S, Zhang H, et al. (2013). Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res.
Applications
WB, IB, PCA
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
